Haverty Furniture Companies, Inc. has announced positive financial results for the third quarter of 2026, showcasing resilience in a challenging economic environment. The company reported a diluted earnings per share of $0.39, up from $0.28 in the same period last year. Consolidated sales increased by 4.5% to $203.2 million, indicating a strong performance despite ongoing economic pressures.
In a press release dated November 4, 2026, Haverty's President and CEO, Steven G. Burdette, highlighted the company’s ability to navigate a soft housing market, rising fuel prices, and increased interest rates. “Our team delivered another quarter of growth, extending our positive momentum in written and delivered comp-store sales against tougher year-over-year comparisons,” Burdette stated.
Background
Haverty Furniture Companies, Inc. is a leading retailer in the furniture industry, classified under the SIC code 5712, which covers retail-furniture stores. The company trades on the New York Stock Exchange under the ticker symbols HVT and HVT-A. Haverty operates primarily in the United States, with its headquarters located in Atlanta, Georgia.
What the Filing Says
According to the SEC filing (accession number 0001628280-26-069778), the third quarter results reflect a 4.1% increase in comparable store sales. The gross profit margin improved to 62.3%, compared to 60.3% in the previous year. Burdette noted that the company is set to open five new stores, including its first location in Pittsburgh, Pennsylvania, expanding its footprint to 133 stores by year-end.
Impact
The results may affect various stakeholders, including investors, employees, and customers. Investors may view the growth positively, while employees could benefit from the company's expansion plans. Customers may see enhanced product offerings and services as Haverty continues to invest in its operations.
What's Next
The filing does not say what happens next.
Read Next
Royalty Pharma reports strong Q3 results, raises guidance
Madison Square Garden Entertainment Reports Strong Q1 Results
NCR Atleos Corp Reports Q3 Results, Highlights Growth Strategy
Viridian Therapeutics reports Q3 2026 financial results
Dine Brands reports strong Q3 results, boosts revenue outlook
Rapport Therapeutics releases Q3 results, highlights growth




